ARQT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcutis Biotherapeutics Inc (ARQT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong revenue growth, its declining net income and EPS, coupled with neutral trading sentiment and lack of significant positive catalysts, suggest a wait-and-see approach. The technical indicators and options data also do not indicate a compelling entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 42.341, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 22.504, with support at 21.782 and resistance at 23.226.
Strong revenue growth in Q4 2025 (+81.48% YoY). Analysts maintain positive ratings with increased price targets, citing strong sales of Zoryve and improved guidance.
Net income and EPS have significantly declined (-261.24% and -255.56% YoY, respectively). No recent news or significant trading activity from insiders or hedge funds. The overall market sentiment is bearish, with SP500 down -1.79%.
In Q4 2025, revenue increased significantly to $129.5M (+81.48% YoY), but net income dropped to $17.4M (-261.24% YoY), and EPS fell to 0.14 (-255.56% YoY). Gross margin slightly improved to 90.97%.
Analysts maintain positive ratings with price targets raised to $34-$35. They are optimistic about the company's commercialization efforts and improved revenue guidance.
